Galectin Therapeutics GALTW 深 沪
等待开盘 04-02 09:30:00 美东时间
0.0425
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0425
- 总市值 0
- 52周最高 0.254
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.024
- 委 比 0.00%
- 总股本 --
- 历史最高 0.254
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.024
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share
03-31 22:19
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs Overview U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027 Outlook Company expe
03-31 20:09
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported that its belapectin program, targeting galectin-3, showed progress in reducing varices and positive biomarker data in patients with MASH cirrhosis. The company secured an additional $10 million line of credit, bolstered its board with Dr. Henry Brem, and saw improved financial stability with reduced R&D expenses, narrowing its net loss.
03-31 12:00
Galectin Therapeutics appoints Henry Brem to board as independent director
Galectin Therapeutics appoints Henry Brem to board as independent director Galectin Therapeutics appointed Henry Brem as an independent director to its board. Brem is the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurg
03-17 19:51
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Galectin Therapeutics Inc. appointed Henry Brem, M.D., as an independent director. Dr. Brem is a leading neurosurgeon-scientist with extensive experience in translational medicine, having developed image-guided surgical techniques and localized drug delivery systems. His expertise will support Galectin’s development of belapectin for patients with MASH cirrhosis and portal hypertension. The company continues to strengthen its board with scientifi...
03-17 12:00
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clini...
02-22 18:42
Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc
Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc Kary Eldred, a director of Galectin Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technolo
02-10 05:25
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt wil
01-22 06:01
BUZZ-U.S. STOCKS ON THE MOVE-Centrus Energy, Generac Holdings
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks climbed on Friday, as ...
2025-12-20 02:56
BRIEF-Galectin Therapeutics Enters Line Of Credit Agreement
Dec 19 (Reuters) - Galectin Therapeutics Inc GALT.O: GALECTIN THERAPEUTICS INC - ENTERS LINE OF CREDIT AGREEMENT - SEC FILING GALECTIN THERAPEUTICS INC - CO SECURES $10 MILLION LINE OF CREDIT - SEC FI...
2025-12-19 21:32
